Lung Cancer
A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), in Combination with Atezolizumab with or without Carboplatin as First-line Induction or Maintenance, in Subjects with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung03) (DS7300-189)
- Details
ClinicalTrials.gov ID:
NCT06362252
Diagnosis Type:
NA
USOR Number:
- Address
,
P: